InsidersTradesSigma
Total declarations
Companies
▲ Purchases (16 ops.)
▼ Sales (6 ops.)
Insider track record
OtherDisclosed buys
16
Disclosed sells
6
T+90 hit rate
100%
T+90 mean return
+40.6%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by Biotech Growth N V. Insider active across 3 companies, notably ESSA Pharma Inc.. Cumulatively, 22 reports have been logged. Split: 16 buys · 6 sells. Total volume traded: €39.1m. History available since 18 August 2021. The latest transaction was disclosed on 19 March 2025 (Cession). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Biotech Growth N V
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations22 total
1,000,000 shares@ US$2.069110.4% of flowCommon StockSEC:0001104659-25-026305:0
2,000,000 shares@ US$1.53212.4% of flowCommon SharesSEC:0000950170-24-121206:0
2,000,000 shares@ US$1.525912.3% of flowCommon SharesSEC:0000950170-24-121206:1
1,879,583 shares@ US$1.51311.5% of flowCommon SharesSEC:0000950170-24-121206:3
2,000,000 shares@ US$1.529412.3% of flowCommon SharesSEC:0000950170-24-121206:2
400,000 shares@ US$2.33524.8% of flowCommon StockSEC:0000950170-23-054142:0
Canonical exit: 15 Jan 2024 (T+90)
1,000,000 shares@ US$5.0025.2% of flowCommon StockSEC:0000950170-23-031386:0
Canonical exit: 28 Sept 2023 (T+90)
1,740,000 shares@ US$5.491447.8% of flowCommon StockSEC:0000899243-23-016705:0
Canonical exit: 25 Sept 2023 (T+90)
99,801 shares@ US$2.25361.2% of flowCommon StockSEC:0000899243-22-034751:0
Canonical exit: 29 Jan 2023 (T+90)
191,678 shares@ US$1.87412.0% of flowCommon StockSEC:0000899243-22-034543:0
Canonical exit: 25 Jan 2023 (T+90)
1,500,000 shares@ US$3.97926.0% of flowCommon SharesSEC:0000899243-22-034401:0
Canonical exit: 24 Jan 2023 (T+90)
87,850 shares@ US$1.51110.7% of flowCommon StockSEC:0000899243-22-034121:0
Canonical exit: 19 Jan 2023 (T+90)
77,689 shares@ US$1.32290.6% of flowCommon StockSEC:0000899243-22-033945:0
Canonical exit: 17 Jan 2023 (T+90)
300,000 shares@ US$3.15584.1% of flowCommon SharesSEC:0000899243-22-026410:0
Canonical exit: 16 Oct 2022 (T+90)
347,204 shares@ US$2.79214.2% of flowCommon SharesSEC:0000899243-22-026225:0
Canonical exit: 12 Oct 2022 (T+90)
150,000 shares@ US$2.66322.1% of flowCommon StockSEC:0000899243-22-016006:0
Canonical exit: 26 Jul 2022 (T+90)
25,100 shares@ US$5.85360.7% of flowCommon SharesSEC:0000899243-22-015831:0
150,000 shares@ US$3.29292.5% of flowCommon StockSEC:0000899243-22-015145:0
Canonical exit: 17 Jul 2022 (T+90)
150,000 shares@ US$3.4242.6% of flowCommon StockSEC:0000899243-22-014768:0
Canonical exit: 11 Jul 2022 (T+90)
250,000 shares@ US$8.87529.1% of flowCommon SharesSEC:0000899243-21-033765:0
Canonical exit: 16 Nov 2021 (T+90)
38,259 sharesCommon StockSEC:0000899243-16-012141:0
Canonical exit: 21 Apr 2016 (T+90)
50,000 sharesCommon StockSEC:0000899243-16-011711:0
Canonical exit: 12 Apr 2016 (T+90)
22 of 22 declarations
About Biotech Growth N V
BIOTECH GROWTH N V has filed 22 disclosures in total. In the 22 most recent filings we hold, the period runs from 2016-01-14 to 2025-03-20, with purchases of EUR 26052846 and sales of EUR 13070716; the companies involved are Black Diamond Therapeutics, Inc., ESSA Pharma Inc. and Radius Health, Inc., where the entity is listed as a 10% Owner for ESSA Pharma Inc. and Radius Health, Inc., and no role is listed for Black Diamond Therapeutics, Inc.
